New and emerging treatment of Staphylococcus aureus infections in the hospital setting

This publication has 53 references indexed in Scilit:

• Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria
  Antimicrobial Agents and Chemotherapy, 2008
• Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus
  Journal of Antimicrobial Chemotherapy, 2007
• Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy
  Expert Opinion on Investigational Drugs, 2007
• In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections
  Antimicrobial Agents and Chemotherapy, 2006
• The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
  Clinical Microbiology & Infection, 2006
• Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance
  Antimicrobial Agents and Chemotherapy, 2005
• Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates
  Diagnostic Microbiology and Infectious Disease, 2004
• In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698
  Journal of Antimicrobial Chemotherapy, 2004
• -lactam Antibiotics Active against Methicillin Resistant Staphylococcus aureus
  The Journal of Infectious Diseases, 1991
• Evolution of an inducible penicillin‐target protein in methicillin‐resistant Staphylococcus aureus by gene fusion
  FEBS Letters, 1987